Clinical Trial

A Comparative, Randomized, Investigator-blind, Active-controlled, Parallel-group, Multicenter, Clinical Endpoint Study

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co., Ltd. compared to LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of AbbVie INC in subjects with primary open angle glaucoma (POAG) or ocular hypertension.
Trial Details
NCT Number NCT07661329
Lead Sponsor YS Life Science Co., Ltd.
Conditions Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
Enrollment 600 participants
Start Date 2026-06-02
Primary Completion 2027-11-01 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-22